Researchers in the #RavetchLab have developed a potential replacement for treating #autoimmunedisease that’s significantly more potent than intravenous immunoglobulin therapy.
Learn more in this Q&A with Jeffrey Ravetch and first author Andrew Jones: https://bit.ly/3KTnzLy
Learn more in this Q&A with Jeffrey Ravetch and first author Andrew Jones: https://bit.ly/3KTnzLy
December 18, 2025 at 8:04 PM
Researchers in the #RavetchLab have developed a potential replacement for treating #autoimmunedisease that’s significantly more potent than intravenous immunoglobulin therapy.
Learn more in this Q&A with Jeffrey Ravetch and first author Andrew Jones: https://bit.ly/3KTnzLy
Learn more in this Q&A with Jeffrey Ravetch and first author Andrew Jones: https://bit.ly/3KTnzLy
Treatments for autoimmune diseases have big shortcomings, including high cost and supply shortages. A alternative developed this year from the #RavetchLab achieves the same effectiveness at a fraction of the dose. #RockefellerScience #YearInReview
🔗: https://bit.ly/3HFdsbs
🔗: https://bit.ly/3HFdsbs
December 27, 2025 at 1:42 PM
Treatments for autoimmune diseases have big shortcomings, including high cost and supply shortages. A alternative developed this year from the #RavetchLab achieves the same effectiveness at a fraction of the dose. #RockefellerScience #YearInReview
🔗: https://bit.ly/3HFdsbs
🔗: https://bit.ly/3HFdsbs
Published in @cp-cancercell.bsky.social, the #RavetchLab demonstrates in a phase 1 clinical trial that an engineered antibody improves a class of cancer drugs—called CD40 agonist antibodies—that has struggled to make good on its early promise. #RockefellerScience
Immunotherapy drug eliminates aggressive cancers in clinical trial - News
The researchers demonstrate that an engineered antibody improves a class of drugs that has struggled to make good on its early promise.
www.rockefeller.edu
August 14, 2025 at 5:41 PM
Published in @cp-cancercell.bsky.social, the #RavetchLab demonstrates in a phase 1 clinical trial that an engineered antibody improves a class of cancer drugs—called CD40 agonist antibodies—that has struggled to make good on its early promise. #RockefellerScience
Current treatments for autoimmune diseases have significant shortcomings, including high cost and supply shortages. A new alternative from the #RavetchLab achieves the same effectiveness when tested in mice at a fraction of the dose. @science.org
Researchers develop a potential IVIG replacement for treating autoimmunity that's significantly more potent - News
The discovery could greatly improve patient experience and address supply shortages.
www.rockefeller.edu
November 6, 2025 at 8:01 PM
Current treatments for autoimmune diseases have significant shortcomings, including high cost and supply shortages. A new alternative from the #RavetchLab achieves the same effectiveness when tested in mice at a fraction of the dose. @science.org